Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Compositions and methods for treating microbiota-related psychotropic conditions and diseases

A technology of mixtures and derivatives, applied in the fields of medicine, gastroenterology, pharmacology and microbiology, can solve unreasonable and painful problems

Active Publication Date: 2016-02-03
托马斯·朱利叶斯·波洛迪
View PDF29 Cites 5 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, people with OCD are able to identify their obsessions and compulsions, and they recognize that they are irrational
this further makes them miserable

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0132] Example 1: Exemplary treatment of OCD in adults with rifaximin

[0133] A 43-year-old woman married to an office worker had suffered from OCD since childhood. After being treated with various medications throughout her life, her behavior patterns are largely under control, except for one behavior: She needs to check gas outlets and electrical outlets every night in case her child is at night due to Injured or damaged by some unforeseen accidents. This is still a "sleep-draining" problem that is not controlled by Zoloft, Clomipramine and other drugs.

[0134] She was started on rifaximin, 500 mg capsules twice daily for the first week and 1 g twice daily thereafter.

[0135] Within 10 days, she noticed that she no longer had to check gas outlets and electrical outlets, and was able to sleep soundly through the night, possibly for the first time in years. This improvement was almost universal over the next 3 months of monitoring their behavior. She is still on long-...

Embodiment 2

[0136] Example 2: Exemplary treatment of OCD in children with rifaximin and vancomycin

[0137] A 13-year-old boy was perfectly healthy until what appeared to be 2-3 weeks of overseas travel and diarrheal illness. Seemingly unrelated, he soon developed the progressive, repetitive behavioral pattern changes diagnosed as OCD over the course of a few months. This is controlled by medication from the leading Institute for Anxiety Disorders. Medications include fluoxetine and escitalopram. He has some of the 56 repetitive behavior patterns recorded by the Institute.

[0138] He was started on escalating doses of vancomycin, 250 mg twice daily, and rifaximin, 550 mg twice daily. After four weeks of treatment, there had been improvement, with a measurable reduction in the OCD pattern. Never being able to go to school or meet his school peers, he has been able to invite friends over as the symptoms bother him less.

[0139] The dose of the vancomycin agent was increased to 500 ...

Embodiment 3

[0142] Aztreonam 50 mg three times daily in a 34-month-old diagnosed with Autism Spectrum Disorder (ASD) who has changes in bowel habits, withdraws from "society" and loss of vocabulary / words / vocalization and decreased socialization and eye contact. About two weeks after starting aztreonam treatment, parents noted "increased socialization" with other children and a decrease in diarrhea, which began to alternate with hard bowel movements. Eye contact increased, but verbal ability did not increase at this stage. Vancomycin at 125mgtds was added and the bowel function improved to a very large volume of expulsion compared to the initial, so it was presumed that the 'constipation' was dealt with. More pertinently, within three months the child appeared to have regained his previous language skills, using at least five more words than before. There is less repetitive movement than before, and there is even eye contact. Treatment continued for more than three months and continued ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
particle size distributionaaaaaaaaaa
fluidityaaaaaaaaaa
Login to View More

Abstract

In alternative embodiments, the invention provides compositions and methods for treating, ameliorating and preventing various disorders and conditions in mammals, including genetically-predisposed and chronic disorders, where the microbial or bacterial flora of the bowel is at least one causative or symptom-producing factor, for example, where the microbial or bacterial flora of the bowel manufactures neurotoxins or neurotoxic agents that enter the body through the gastrointestinal (Gl) tract, e.g. the colon, and reach the systemic space, e.g., by neural streaming or via the circulation, to reach the central nervous system (CNS), including the brain, the peripheral nervous system (PNS), and other nervous systems. In alternative embodiments, methods and compositions of the invention comprise or comprise use of medications, formulations and pharmaceuticals comprising rifaximin or equivalent active agents that can suppress or eradicate the microbiota super-infection that causes various psychotropic disorders. These compositions have been found to be affective in a broad spectrum of disorders but particularly in the obsessive compulsive disorder group (OCD).

Description

technical field [0001] The invention generally relates to medicine, gastroenterology, pharmacology, and microbiology. In alternative embodiments, the present invention provides compositions and methods for treating, ameliorating, and preventing various disorders and conditions in mammals, including genetically predisposed disorders and chronic disorders, wherein intestinal The microorganisms or bacterial flora in the gut are at least one causative or symptom-producing factor, for example where the microorganisms or bacterial flora in the gut produce neurotoxins or neurotoxic agents, which enter the body through the gastrointestinal (GI) tract (e.g., the colon) and Access to systemic spaces, eg, via neural streams or via circulation to the central nervous system (CNS), peripheral nervous system (PNS), and other nervous systems including the brain. In alternative embodiments, the methods and compositions of the invention include or include the use of medicaments, formulations a...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/437A61K38/14A61K31/427A61K31/7036A61K9/28A61P25/00
CPCA61K38/14A61K31/427A61K31/7036A61K9/0056A61K45/06A61K31/7042A23L33/10A61K31/437A61P25/00A61P43/00Y02A50/30A61K2300/00A23L35/00A61K31/4164
Inventor 托马斯·朱利叶斯·波洛迪
Owner 托马斯·朱利叶斯·波洛迪
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com